tiprankstipranks
Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
US Market
MAZE
Maze Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see MAZE full AI Analyst Report?

Maze Therapeutics, Inc. (MAZE) Stock News & Sentiment

92 Followers
Maze Therapeutics prices $150 million equity offering
Premium
Company Announcements
Maze Therapeutics prices $150 million equity offering
8d ago
8K
MAZE
MAZE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
MAZE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
26d ago
MAZE
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
Premium
Ratings
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
1M ago
MAZE
Maze Therapeutics adds Neil Kumar to board leadership
Premium
Company Announcements
Maze Therapeutics adds Neil Kumar to board leadership
1M ago
8K
MAZE
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
Premium
Ratings
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
2M ago
MAZE
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside
Premium
Ratings
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside
2M ago
MAZE
Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst
Premium
Ratings
Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst
2M ago
MAZE
More MAZE News >

MAZE News on the Web

Squadron Capital Management LLC Acquires 7,608,695 Shares in SCYNEXIS Inc
GuruFocus News
Neutral
Maze Therapeutics price target lowered to $64 from $68 at Truist
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Immuneering (IMRX) and Maze Therapeutics, Inc. (MAZE)
TipRanks News
Neutral
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Neutral
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
The Motley Fool
Bearish
MAZE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
TipRanks News
Neutral
J.P. Morgan Sticks to Its Buy Rating for Maze Therapeutics, Inc. (MAZE)
TipRanks News
Neutral
Maze Therapeutics price target raised to $58 from $52 at JPMorgan
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
MAZE
Sector Average
Media Buzz
Currently, no data available
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MAZE’s Media Buzz Sentiment?
Currently, no data Available
What is MAZE’s weekly average amount of articles?
Currently, no data Available
What is MAZE’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
TVTXTravere Therapeutics
HVOOpen Orphan Plc
PBMPsyence Biomedical
QDELQuidelOrtho
Showing the stocks with the most bullish news sentiment over the past week